Rivaroxaban and early periprostethic joint infection: our experience

Rivaroxaban and early periprostethic joint infection: our experience


  • Paolo Di Benedetto
  • Andrea Zangari
  • Dania De Franceschi
  • Enrico Daniele Di Benedetto
  • Vanni Cainero
  • Alessandro Beltrame
  • Renato Gisonni
  • Araldo Causero


acute early periprostethic joint infection, Rivaroxaban, Total Hip Arthroplasty


Background and aim of the work: Periprostethic joint infection (PJI) is a severe post-operative complication after Primary Total Hip Arthroplasty (THA). According to the classification of PJI early acute PJI occurs within 4 weeks from surgery. Some authors think that Rivaroxaban is a risk factor in the incidence of early acute PJI. We analyze our experience about this item. Materials and methods: We analyze our experience from 1st January 2015 to 31th December 2016. We consider all consecutive hip arthroplasty implants in this period. Results: In the 205 patients analysed we not find early acute PJI in Rivaroxaban group nor in the others assuming another kind of thromboprophylaxis. Conclusions: In our series there is no evidence of association between Rivaroxaban and early acute PJI. This is a retrospective cohort study, so we need more studies and more robust experimental designs to confirm these results. 







How to Cite

Di Benedetto P, Zangari A, De Franceschi D, Di Benedetto ED, Cainero V, Beltrame A, et al. Rivaroxaban and early periprostethic joint infection: our experience. Acta Biomed [Internet]. 2017 Oct. 18 [cited 2024 Jul. 21];88(4 -S):38-42. Available from: https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/6792